In a groundbreaking study, researchers have found that 84.4% of cancer patients treated with a combination of ivermectin and mebendazole showed no evidence of disease, tumor regression, or cancer stabilization after six months. The findings, published in the Public Health Policy Journal, suggest a potential breakthrough in cancer treatment using repurposed drugs.
Ivermectin, traditionally used as an antiparasitic medication, and mebendazole, an antihelminthic, have been at the center of various studies exploring their potential anticancer properties. This latest research involved a cohort of cancer patients who were administered the drug combination over a six-month period. According to sources familiar with the study, the results indicate a significant reduction in tumor size and stabilization in the majority of the participants.
“This study opens up new possibilities for cancer treatment,” said one analyst, who requested anonymity due to the preliminary nature of the findings. “Repurposing existing drugs could provide a cost-effective and accessible option for patients worldwide.”
However, the study has its critics. Some experts caution that more extensive clinical trials are needed to confirm the efficacy and safety of the treatment. “While the results are promising, we need to ensure that this combination does not pose unintended risks,” noted a spokesperson from the American Cancer Society.
The implications of this study are profound. If further research corroborates these findings, it could lead to the development of new cancer therapies that are both affordable and effective. The next steps involve larger, controlled trials to validate the outcomes and explore potential side effects.